P-tau

P-tau

, p-Tau (pē′tow′)
Tau protein that is abnormally phosphorylated. Its concentrated presence in the cerebrospinal fluid is indicative of Alzheimer disease.
References in periodicals archive ?
The researchers found that people who have higher pulse pressure are more likely to have the Alzheimer's biomarkers amyloid-beta, or plaques, and p-tau protein, or tangles, in their cerebral spinal fluid than those with lower pulse pressure.
Kester and her colleagues explored the relationship between small-vessel disease pathology and AD pathology by assessing MRI images of microbleeds, white-matter hyperintensities, and lacunes and correlating these with CSF (cerebrospinal fluid) levels of beta-amyloid 42, total tau, and p-tau.
The study found that people who have higher pulse pressure are more likely to have the Alzheimer's biomarkers amyloid beta, or plaques, and p-tau protein, or tangles, in their cerebral spinal fluid than those with lower pulse pressure.
Their models produce cognitive impairment, as assessed in the Morris Water Maze, and increase expression of tau, p-tau, APP, A[sz] and alpha-synuclein in the brain.
11) provide in vivo evidence for an association between disrupted methylation and P-tau accumulation.
The CSF based P-Tau 231 test now being offered for use in clinical trials can effectively differentiate AD patients from those with other neurological diseases that have similar symptoms.
The decrease in the concentration of mtDNA precedes the appearance of well-known biochemical Alzheimer's biomarkers (the A[beta]1-42, t-tau, and p-tau proteins), suggesting that the pathophysiological process of Alzheimer's disease starts earlier than previously thought.
All subjects had cerebrospinal fluid drawn for Abeta42, tau, and P-tau levels.
When the researchers did consider body mass, they found that lean patients (defined as having a body mass index less than 25) with SDB did possess several specific and non-specific biomarkers of AD risk (increased P-Tau and T-Tau in CSF, hippocampal atrophy using structural MRI, and glucose hypometabolism using FDG-PET in several AD-vulnerable regions).
The amount of P-tau in cerebrospinal fluid (CSF) is believed to be a marker of active loss of brain cells in people with Alzheimer's; prior studies have shown increases in P-tau in people with mild cognitive impairment who later develop Alzheimer's.
Increased P-tau may be related to a lower phosphatase activity or to increased activity of kinases (see Fig.